
Biomerica BMRA
$ 2.3
-4.56%
Quarterly report 2026-Q1
added 04-13-2026
Biomerica Total Non Current Liabilities 2011-2026 | BMRA
Annual Total Non Current Liabilities Biomerica
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 1.57 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.57 M | 1.57 M | 1.57 M |
Total Non Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Co-Diagnostics
CODX
|
574 K | $ 1.29 | -20.86 % | $ 1.72 M | ||
|
Centogene N.V.
CNTG
|
23.7 M | - | -6.23 % | $ 30.6 M | ||
|
Fulgent Genetics
FLGT
|
2.26 M | $ 15.71 | -2.96 % | $ 475 M | ||
|
Agilent Technologies
A
|
3.29 B | $ 111.77 | -1.3 % | $ 34 B | ||
|
Castle Biosciences
CSTL
|
2.76 M | $ 19.2 | 1.69 % | $ 557 M | ||
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
3.49 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | ||
|
Illumina
ILMN
|
2.04 B | $ 143.1 | -0.1 % | $ 22.8 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M | ||
|
Interpace Biosciences
IDXG
|
10 M | $ 1.8 | - | $ 7.96 M | ||
|
CareDx, Inc
CDNA
|
17.9 M | $ 20.02 | -2.29 % | $ 1.07 B | ||
|
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
16 K | - | - | $ 9.42 M | ||
|
Lantheus Holdings
LNTH
|
225 M | $ 94.21 | -2.55 % | $ 6.36 B | ||
|
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | ||
|
Mettler-Toledo International
MTD
|
1.61 B | $ 1 034.95 | -0.67 % | $ 21.3 B | ||
|
Medpace Holdings
MEDP
|
73.8 M | $ 417.68 | -0.36 % | $ 12 B | ||
|
Global Cord Blood Corporation
CO
|
2.53 B | - | - | $ 399 M | ||
|
Myriad Genetics
MYGN
|
107 M | $ 3.59 | -0.97 % | $ 332 M | ||
|
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
559 K | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
48.5 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | ||
|
NeoGenomics
NEO
|
435 M | $ 8.26 | -1.2 % | $ 1.06 B | ||
|
Charles River Laboratories International
CRL
|
2.35 B | $ 150.9 | -5.17 % | $ 7.48 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
1.43 B | - | - | $ 10.7 B | ||
|
National Research Corporation
NRC
|
39.6 M | $ 18.56 | -1.95 % | $ 415 M | ||
|
Natera
NTRA
|
124 M | $ 188.46 | -4.22 % | $ 18.5 B | ||
|
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | ||
|
Exact Sciences Corporation
EXAS
|
981 M | - | - | $ 19.8 B | ||
|
Koninklijke Philips N.V.
PHG
|
8.45 B | $ 25.24 | -1.02 % | $ 23.9 B | ||
|
Guardant Health
GH
|
91.4 M | $ 95.46 | -3.24 % | $ 12 B | ||
|
Senseonics Holdings
SENS
|
163 M | $ 5.76 | -1.12 % | $ 240 M | ||
|
Personalis
PSNL
|
639 K | $ 6.4 | -4.69 % | $ 571 M | ||
|
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | ||
|
ICON Public Limited Company
ICLR
|
461 M | $ 115.74 | -1.15 % | $ 9.55 B | ||
|
Soleno Therapeutics
SLNO
|
10.8 M | $ 53.0 | 0.01 % | $ 2.69 B | ||
|
QIAGEN N.V.
QGEN
|
1.99 B | - | - | $ 10.6 B | ||
|
Laboratory Corporation of America Holdings
LH
|
7.82 B | $ 251.69 | -0.92 % | $ 20.9 B | ||
|
Thermo Fisher Scientific
TMO
|
22.5 B | $ 438.03 | -2.27 % | $ 165 B | ||
|
Trinity Biotech plc
TRIB
|
106 M | $ 0.56 | -3.63 % | $ 201 M | ||
|
Celcuity
CELC
|
69.2 K | $ 137.57 | 2.12 % | $ 6.43 B | ||
|
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | ||
|
Twist Bioscience Corporation
TWST
|
4.56 M | $ 49.03 | -7.4 % | $ 2.93 B | ||
|
Neogen Corporation
NEOG
|
19.6 M | $ 8.18 | -3.02 % | $ 1.77 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 187.21 | -0.39 % | $ 20.8 B | ||
|
Waters Corporation
WAT
|
1.28 B | $ 331.36 | -0.56 % | $ 19.7 B |